Interest in Precision Medicine Grows, But Reimbursements Slow
By Andrew Joseph,
Stat News
| 12. 23. 2015
Untitled Document
Precision medicine, in which drugs are matched to individual patients, has generated tons of buzz, from patient organizations all the way to the White House. But insurers have been grappling with whether to pay for the genetic tests that often guide such treatments, and that uncertainty has had ripple effects through the biotech companies working to develop them.
The case of Foundation Medicine, based in Cambridge, Mass., demonstrates the quest companies sometimes have to undertake to get their products covered, a process complicated when that product is a cutting-edge technology insurers aren’t sure how to assess.
Foundation analyzes the genes of a patient’s tumor to identify what’s driving the cancer and, from that, to determine what treatment will work best. The company announced this week that UnitedHealth Group had started covering its genetic test for patients with a certain lung cancer. That decision, by the country’s largest private health insurer, represents a milestone for the company as it looks to strike deals with more insurers.
Read more...
Image via Flickr.
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
